Derek J. Maetzold, President and Chief Executive Officer, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 59 transactions, Maetzold has sold shares totaling approximately $8.83 million while purchasing shares worth just $16,194.64, all within a single company, Castle Biosciences Inc. (ticker: CSTL). Notably, his recent trades, spanning from February to March 2026, have been exclusively sales, with 17 transactions recorded during this period. These sales ranged in value from $3,361.68 to $585,941.94, with significant transactions on March 11 and March 12, 2026, totaling $451,946.79 and $585,941.94, respectively. Additionally, Maetzold engaged in several smaller sales, such as $7,103.18 and $14,053.05 on March 26, 2026, alongside a minor acquisition of $1,314.50 on the same date. The absence of recent purchases and the consistent pattern of divestment suggest a strategic reduction in his holdings in CSTL. This activity aligns with his broader trading history, which leans heavily toward selling, reflecting a notable shift away from accumulating shares in the company he leads.
AI-assisted summary